IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Bridges Investment Management Inc.

Bridges Investment Management Inc. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 10.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,374 shares of the medical research company’s stock after selling 158 shares during the period. Bridges Investment Management Inc.’s holdings in IQVIA were worth $318,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp lifted its position in IQVIA by 2.5% in the second quarter. State Street Corp now owns 8,451,571 shares of the medical research company’s stock worth $1,899,660,000 after purchasing an additional 207,148 shares during the period. Alliancebernstein L.P. lifted its position in IQVIA by 19.1% in the second quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock worth $1,335,754,000 after purchasing an additional 952,850 shares during the period. Geode Capital Management LLC lifted its position in IQVIA by 2.2% in the first quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock worth $754,864,000 after purchasing an additional 81,501 shares during the period. Lazard Asset Management LLC lifted its position in IQVIA by 2.9% in the third quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after purchasing an additional 80,189 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in IQVIA by 3.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock worth $457,483,000 after purchasing an additional 77,422 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.7 %

NYSE:IQV traded down $1.72 during trading hours on Wednesday, hitting $243.79. 86,721 shares of the stock traded hands, compared to its average volume of 1,004,982. The firm has a 50 day moving average price of $238.60 and a 200 day moving average price of $218.55. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The firm has a market cap of $44.25 billion, a price-to-earnings ratio of 33.68, a PEG ratio of 2.41 and a beta of 1.50.

IQVIA (NYSE:IQVGet Free Report) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same period in the previous year, the business earned $2.54 EPS. The company’s revenue was up 3.5% on a year-over-year basis. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on IQV shares. UBS Group upped their target price on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Citigroup upped their price target on IQVIA from $190.00 to $225.00 and gave the company a “neutral” rating in a report on Monday, December 11th. BTIG Research assumed coverage on IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target on the stock. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, SVB Leerink assumed coverage on IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target on the stock. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $256.80.

Read Our Latest Analysis on IQVIA

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock worth $10,331,003. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.